Skip to content
Catalyst Biosciences
Primary Menu
About
Overview
Management Team
Board of Directors
Pipeline
Overview
Complement
Partnering Opportunties
Science
Overview
Publications
Clinical Trials
Investors
Press Releases
Events and Presentations
Events
Presentations
Scientific Presentations and Publications
Financials & Filings
Stock Information
Stock Quote
Stock Chart
Corporate Governance
Leadership Team
Board of Directors
Committee Composition
Investor FAQ
Careers
Career Opportunities
Benefits
Values
Contact
AAV Based Hemophilia B Gene Therapy in Mice Using FIX-CB2679d-GT
Post navigation
Previous:
Phase 2/3 Trial of Subcutaneously Administered Marzeptacog Alfa (Activated) An Engineered FVIIa In Hemophilia With Inhibitors -Pharmacokinetics, Pharmacodynamics, Safety and Efficacy
Next:
CB 2782-PEG: a Complement Factor C3-Inactivating Protease and Potential Long-Acting Treatment for Dry AMD
X
Previous
Next
